Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
12 hedge funds and large institutions have $21.4M invested in Celyad Oncology SA American Depositary Shares in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
35% more capital invested
Capital invested by funds: $15.9M → $21.4M (+$5.5M)
33% more funds holding
Funds holding: 9 → 12 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$5.48M |
| 2 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
+$1.18M |
| 3 |
Millennium Management
New York
|
+$577K |
| 4 |
EP
Eversept Partners
New York
|
+$394K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$32.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$586K |
| 2 |
Morgan Stanley
New York
|
-$116K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $18.7M | +$5.48M | +178,380 | +42% |
|
|
SLG
2
Stanley-Laman Group
Berwyn,
Pennsylvania
| $1.15M | +$1.18M | +38,525 | New |
|
|
3
Millennium Management
New York
| $582K | +$577K | +18,781 | New |
|
|
EP
4
Eversept Partners
New York
| $382K | +$394K | +12,840 | New |
|
5
Renaissance Technologies
New York
| $205K | +$10.4K | +340 | +5% |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $181K | +$32.5K | +1,058 | +21% |
|
|
7
Morgan Stanley
New York
| $70K | -$116K | -3,790 | -62% |
|
8
UBS Group
Zurich,
Switzerland
| $54K | +$10.8K | +351 | +24% |
|
9
Wells Fargo
San Francisco,
California
| $15K | +$15.4K | +500 | New |
|
10
Bank of Montreal
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
11
Zurich Cantonal Bank
Zurich,
Switzerland
| $3K | – | – | – |
|
12
US Bancorp
Minneapolis,
Minnesota
| $2K | +$2.43K | +79 | New |
|
|
13
Jane Street
New York
| – | -$586K | -16,816 | Closed |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$1K | -32 | Closed |
|
CYAD Hedge Fund Activity: Q2 2018 in Review
12 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q2 2018, worth a combined $21.4M — up 35% from $15.9M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CYAD positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $5.48M. The largest seller was Jane Street, exiting entirely with an estimated $586K sold.
- 12 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q2 2018, up from 9 in Q1 2018.
- Funds reported $21.4M of Celyad Oncology SA American Depositary Shares stock for Q2 2018, up 35% quarter-over-quarter.
- 5 funds opened new Celyad Oncology SA American Depositary Shares positions in Q2 2018 and 2 closed out, a net change of +3 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q2 2018 was Victory Capital Management, an estimated $5.48M added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q2 2018 was Jane Street, an estimated $586K sold.
Based on aggregated 13F filings for Q2 2018.